US sales in Q1 is estimated at USD 270-276 million from USD 285 million (QoQ), due to pricing pressure in drugs such as Valcyte & Vidaza generic. Also, there may be some pressure in US due to market share loss in Sumatriptan auto-injector and Dacogen generic.
first published: Jul 25, 2016 12:00 pm
A collection of the most-viewed Moneycontrol videos.
Nifty Sideways But Holds 26,000 Ahead Of MPC Rate Decision| IT & Realty Upbeat| Closing Bell Live
Live: RBI Policy Expectations| Rupee Slide, Strong GDP & Soft Inflation – Will MPC Cut Or Pause?
Nifty Holds Key Support; Volatile Trade Likely on Sensex Expiry | Opening Bell Live
Rupee Slide Weighs Heavy As Nifty Tests 25,900| Midcaps See Sharp Cuts| Closing Bell Live
